Published in Cell on January 29, 2015
Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency. Cell (2016) 1.84
Broadly Neutralizing Antibody 8ANC195 Recognizes Closed and Open States of HIV-1 Env. Cell (2015) 1.16
Antibody-Based Strategies to Prevent and Treat Influenza. Front Immunol (2015) 0.88
Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization. J Virol (2015) 0.88
Mechanisms of Ricin Toxin Neutralization Revealed through Engineered Homodimeric and Heterodimeric Camelid Antibodies. J Biol Chem (2015) 0.88
Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. Nat Struct Mol Biol (2016) 0.88
Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas. MBio (2015) 0.87
Progress toward active or passive HIV-1 vaccination. J Exp Med (2016) 0.86
Engineering broadly neutralizing antibodies for HIV prevention and therapy. Adv Drug Deliv Rev (2016) 0.86
Towards HIV-1 remission: potential roles for broadly neutralizing antibodies. J Clin Invest (2016) 0.85
Antibody engineering for increased potency, breadth and half-life. Curr Opin HIV AIDS (2015) 0.83
Quantitative Correlation between Infectivity and Gp120 Density on HIV-1 Virions Revealed by Optical Trapping Virometry. J Biol Chem (2016) 0.83
Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1. Viruses (2015) 0.82
The Density Code for the Development of a Vaccine? J Pharm Sci (2016) 0.77
How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses. Expert Rev Vaccines (2016) 0.77
DNA-based control of protein activity. Chem Commun (Camb) (2016) 0.76
Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. Curr Opin HIV AIDS (2017) 0.76
Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. Curr Opin HIV AIDS (2017) 0.75
Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies. J Acquir Immune Defic Syndr (2016) 0.75
Engineering antibody-like inhibitors to prevent and treat HIV-1 infection. Curr Opin HIV AIDS (2017) 0.75
Engineering antibody-like inhibitors to prevent and treat HIV-1 infection. Curr Opin HIV AIDS (2017) 0.75
Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library. Sci Rep (2017) 0.75
Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity. Microbiol Mol Biol Rev (2016) 0.75
Intracellular Crosslinking of Filoviral Nucleoproteins with Xintrabodies Restricts Viral Packaging. Front Immunol (2017) 0.75
Computational design of trimeric influenza-neutralizing proteins targeting the hemagglutinin receptor binding site. Nat Biotechnol (2017) 0.75
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science (2011) 9.00
Molecular architecture of native HIV-1 gp120 trimers. Nature (2008) 8.04
Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature (2006) 6.78
Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol (2005) 6.23
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol (2009) 5.91
Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (2013) 5.53
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature (2012) 5.44
The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J Virol (1992) 5.30
Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science (2013) 4.61
Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science (2011) 4.30
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature (2010) 3.96
Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature (2014) 3.50
NUPACK: Analysis and design of nucleic acid systems. J Comput Chem (2011) 3.33
Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A (2012) 3.33
Antibodies in HIV-1 vaccine development and therapy. Science (2013) 3.13
Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathog (2012) 3.07
Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci U S A (2013) 2.96
Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody. Nat Struct Mol Biol (2006) 2.50
Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell (2014) 2.36
Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein increases env incorporation into particles and fusogenicity and infectivity. J Virol (1993) 2.34
Neutralization of poliovirus by a monoclonal antibody: kinetics and stoichiometry. Virology (1983) 2.30
Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry. PLoS Pathog (2007) 2.14
Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science (2014) 2.05
Antibody elbow angles are influenced by their light chain class. J Mol Biol (2006) 1.96
Few and far between: how HIV may be evading antibody avidity. PLoS Pathog (2010) 1.94
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A (2011) 1.85
Prefusion structure of trimeric HIV-1 envelope glycoprotein determined by cryo-electron microscopy. Nat Struct Mol Biol (2013) 1.80
Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol (2005) 1.80
Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1. Proc Natl Acad Sci U S A (2013) 1.76
Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc Natl Acad Sci U S A (2009) 1.74
Determination of DNA persistence length by cryo-electron microscopy. Separation of the static and dynamic contributions to the apparent persistence length of DNA. J Mol Biol (1995) 1.73
Polymer models of protein stability, folding, and interactions. Biochemistry (2004) 1.57
Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc Natl Acad Sci U S A (2013) 1.51
Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy. Science (2012) 1.50
Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. Sci Transl Med (2014) 1.49
Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12. J Virol (2003) 1.45
High sensitivity multianalyte immunoassay using covalent DNA-labeled antibodies and polymerase chain reaction. Nucleic Acids Res (1995) 1.34
Structure and stability of designed TPR protein superhelices: unusual crystal packing and implications for natural TPR proteins. Acta Crystallogr D Biol Crystallogr (2007) 1.33
Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization. Virology (2008) 1.26
Site-specific C-terminal and internal loop labeling of proteins using sortase-mediated reactions. Nat Protoc (2013) 1.25
Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody. AIDS Res Hum Retroviruses (2004) 1.24
HIV-1 envelope glycoprotein structure. Curr Opin Struct Biol (2013) 1.19
Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection. J Antimicrob Chemother (2010) 1.07
Single-chain Fv-based anti-HIV proteins: potential and limitations. J Virol (2011) 1.07
Variations in the neutralizing and haemagglutination-inhibiting activities of five influenza A virus-specific IgGs and their antibody fragments. J Gen Virol (1997) 1.05
Production of unnaturally linked chimeric proteins using a combination of sortase-catalyzed transpeptidation and click chemistry. Nat Protoc (2013) 0.92
Mutation of critical serine residues in HIV-1 matrix result in an envelope incorporation defect which can be rescued by truncation of the gp41 cytoplasmic tail. Virology (2008) 0.88
Aggregate complexes of HIV-1 induced by multimeric antibodies. Retrovirology (2014) 0.85
Design and characterization of structured protein linkers with differing flexibilities. Protein Eng Des Sel (2014) 0.84
Binding parameters of antibodies: pseudo-affinity and other misconceptions. Cancer Immunol Immunother (2004) 0.81
Dynamic light scattering study of peanut agglutinin: size, shape and urea denaturation. J Biosci (2006) 0.80
Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep (2014) 2.01
Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell (2014) 1.91
Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci Transl Med (2014) 1.60
Anti-PolyQ Antibodies Recognize a Short PolyQ Stretch in Both Normal and Mutant Huntingtin Exon 1. J Mol Biol (2015) 0.79